A retrospective analysis comparing 30 crizotinib-treated ALK-positive NSCLC patients to 23 crizotinib-naïve ones reported longer OS in the former (1-year OS: 70% vs. 44%; 2-year OS: 55% vs. 12%, respectively) [5]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.